Orlance, Inc. and Product Creation Studio Forge Partnership for MACH-1 System Development

SEATTLE, WA - Orlance, Inc., a leading biotech firm, has partnered with Product Creation Studio (PCS) to advance the design of the innovative MACH-1 system, which is geared towards needle-free delivery of DNA and RNA vaccines and therapeutics. This collaboration is set to propel the MACH-1 system into Phase 1 clinical trials, with a focus on enhancing its design for rapid progression through subsequent trial phases and market launch.

The strategic partnership aims to fuse PCS's extensive experience in product development with Orlance's scientific expertise. This synergy is expected to facilitate technical advancements in the MACH-1 system, thereby accelerating its clinical and commercial timelines. Kristyn Aalto, CEO of Orlance, highlighted the partnership's benefits, emphasizing the efficient utilization of PCS's resources to focus more on crucial scientific goals. Scott Thielman, CTO of PCS, also expressed enthusiasm about supporting Orlance's innovative approaches to vaccine and immunotherapy development.